Skip to content
Drug Policy Watch™
LatestTracking drug policy in all 50 states and Congress, updated every morning.See all ›
Drug Policy Watch · State Brief 2026

Kansas

Snapshot (structured)

Adult-use cannabis
Illegal. No legalization law. Possession is a crime.
Medical cannabis
Illegal. No functional medical program. Kansas is one of a small handful of states with no comprehensive medical cannabis law.
Home grow
Not permitted (no legal cannabis framework of any kind).
Intoxicating hemp / hemp THC
Legal in a limited and contested form. Hemp-derived products at or below 0.3 percent total THC are permitted; state authorities read the 0.3 percent cap as total THC, not just delta-9. Inhalable formats (vapes, cigarettes, cigars, loose flower) are restricted at retail per industry guides; THCA edibles, tinctures, and topicals are sold. Exposed to the federal closure effective November 12, 2026.
Psychedelics
Illegal. No decriminalization. The only active legislative thread is a narrow carve-out tied to a future FDA-approved psilocybin drug (Compass Pathways), not general access.
Broad decriminalization
No. Senate President has said marijuana will not be decriminalized while he holds power.
Harm reduction
Partial. Naloxone distributed statewide; fentanyl test strips legalized in 2023. Syringe service programs remain illegal. No Good Samaritan overdose immunity law as of latest reporting.
Governor (party)
Laura Kelly (Democrat), term-limited, in her final year.
Legislature control
Republican veto-proof supermajority in both chambers (Senate roughly 31-9, House roughly 88-37 after the 2024 elections).
Citizen ballot initiatives allowed
No. Kansas has no statewide initiative or referendum process.
Enclosure pressure score
5/5

Cannabis

Adult-use cannabis is illegal in Kansas, with no legalization law (status as of 2026). Medical cannabis is also illegal; Kansas remains one of the very few states without a functional, comprehensive medical cannabis program (MPP; Kansas State Cannabis; This is Topeka, March 2026). Because there is no legal cannabis framework, there is no home grow, no licensing, no MSO presence, no vertical integration regime, and no cannabis tax structure to describe. The market structure for cannabis is, in effect, prohibition.

The only narrow legal exception is Claire and Lola's Law (SB 282, 2018), which provides an affirmative defense for possession of CBD oil containing no more than 5 percent THC for individuals with qualifying seizure disorders (Kansas State Cannabis). First-offense marijuana possession can carry up to 6 months in jail and a fine up to 1,000 dollars (Kansas State Cannabis).

Key 2026 actions: Multiple cannabis bills were filed for the 2025-2026 biennium (medical bills SB 294 and HB 2678, adult-use bills HB 2405 and HB 2679), but none advanced. The legislature adjourned on April 10, 2026 without moving any of them; several never received a hearing (MPP; The Cannabis Business Advisors). Senate President Ty Masterson has repeatedly blocked medical cannabis, including rerouting a House-passed measure into a leadership-controlled committee in a prior session, and has stated marijuana will not be decriminalized while he is in power (MPP, hearings cancelled).

Hemp

Hemp-derived products are legal in Kansas at or below 0.3 percent THC, but the state takes a stricter posture than the federal floor: Kansas authorities interpret the 0.3 percent ceiling as total THC (including delta-8 and other isomers), not delta-9 alone (Burning Daily / BD Logistics; ATLRx). Per industry guides, inhalable hemp formats such as vapes, cigarettes, cigars, teas, and loose flower are restricted at retail, while compliant THCA edibles, tinctures, and topicals are available (Burning Daily). These are vendor and trade-press readings and the exact enforcement line is uncertain; treat the inhalable-versus-edible distinction as industry interpretation rather than a single clear statute.

Effective January 1, 2025, hemp producer licensing in Kansas transitioned from the Kansas Department of Agriculture to the USDA federal program, meaning producers now license directly through USDA (Cannabis Regulations AI; Kansas Department of Agriculture).

Recent state action: SB 292 (2025-2026) would impose age-21 sales restrictions, new labeling requirements, and potential potency caps on intoxicating hemp. As of reporting it remained in committee and did not pass (Cannabis Regulations AI).

Federal exposure and the November 12, 2026 deadline: The Continuing Appropriations Act, 2026, signed in November 2025, rewrites the federal definition of hemp and bans most intoxicating hemp products. The change takes effect November 12, 2026, after which most hemp-derived and synthetic THC products (delta-8, THCA, and similar) would lose their federal legal footing (Herb; Legislative Analysis and Public Policy Association fact sheet; Manzuri Law). Because Kansas already reads its THC cap as total THC and restricts many inhalable formats, the federal change would tighten an already constrained market rather than overturn a permissive one. The precise interaction between the federal closure and Kansas enforcement after November 12, 2026 is unconfirmed.

Psychedelics

Psychedelics are illegal in Kansas, with no decriminalization or general therapeutic-access framework (Tripsitter; World Population Review).

The only meaningful legislative thread is a narrow pharmaceutical carve-out. A lobbyist requested HB 2218 on behalf of Compass Pathways to exempt an FDA-approved form of psilocybin (the company's COMP360 25 mg capsule for treatment-resistant depression) from the state controlled substances act in advance of possible federal approval. This bill would not decriminalize or legalize psilocybin generally and would not allow access to non-FDA-approved forms (Kansas Reflector, Feb 2025). The status of HB 2218 in the 2026 session is unconfirmed; treat it as a pharma-access bill, not a reform bill.

Note for the record: a prior broad psilocybin legalization bill (decriminalizing possession up to 50 grams and home cultivation) was filed by Rep. Aaron Coleman in 2022, not in 2026. It is historical context, not active 2026 legislation (Marijuana Moment).

Broader drug policy

Decriminalization: There is no broad drug decriminalization in Kansas, and marijuana itself is not decriminalized. Senate leadership has signaled continued opposition (MPP).

Harm reduction: - Naloxone: Distributed statewide. DCCCA provides free naloxone nasal spray, fentanyl test strips, and training to community organizations and Kansas residents (DCCCA). Effective July 1, 2026, HB 2250 allows naloxone to be used up to 10 years past its printed expiration date (DCCCA); the bill number and effective date are reported via that program source and the specific statutory citation is otherwise unconfirmed. - Fentanyl test strips / drug checking: Legalized in 2023 (bipartisan bill signed by Gov. Kelly). Possession is no longer a crime, and pharmacies, online retailers, and harm-reduction programs may distribute them. Kansas permits testing equipment for fentanyl, fentanyl analogs, ketamine, and gamma hydroxybutyric acid (Kansas Reflector, May 2023; KCUR). - Syringe service programs: Remain illegal. Kansas has not legalized syringe exchange (KCUR). - Good Samaritan overdose immunity: Reporting indicates Kansas had not adopted a Good Samaritan overdose law as of the fentanyl-test-strip coverage; current status unconfirmed.

Sentencing and expungement: Cannabis is illegal, but Kansas general expungement law lets a convicted person petition the court after discharge from probation or parole, with waiting periods of about 3 years for misdemeanors and minor felonies and about 5 years for more serious felonies or DUI. Serious violent offenses are ineligible (Collateral Consequences Resource Center; CriminalDefenseLawyer.com). Expungement is petition-based, not automatic, and not cannabis-specific.

Political landscape

Governor: Laura Kelly (Democrat), term-limited and serving her final year in 2026 (Kansas Reflector, Jan 2026). The August 4, 2026 primary will set her successor field; Republican candidates include Senate President Ty Masterson, Secretary of State Scott Schwab, and Insurance Commissioner Vicki Schmidt; Democratic candidates include state senators Cindy Holscher and Ethan Corson (KCUR).

Party control: Republicans hold a veto-proof supermajority in both chambers (Senate roughly 31-9, House roughly 88-37 following the 2024 elections), against a Democratic governor, producing divided government in which the GOP can override vetoes (KSNT; Ballotpedia, party control). In April 2026, the GOP overrode many of Kelly's vetoes (The Beacon).

Named opponent: Senate President Ty Masterson (R) is the principal gatekeeper against cannabis reform. He has rerouted a House-passed medical cannabis bill into the leadership-controlled Committee on Interstate Cooperation that he chairs, and has said marijuana will not be decriminalized while he is in power (MPP).

Named reform proponents: Democratic legislators sponsoring the 2026 cannabis bills, including Rep. Ford Carr (reported primary sponsor of adult-use HB 2679) and Rep. L. Ruiz (among medical HB 2678 sponsors). Full named sponsor lists are unconfirmed; verify via the trackers before citing individual legislators (LegiScan HB 2679; LegiScan HB 2678).

Key committees: Senate Committee on Federal and State Affairs (where SB 294 died) and the Committee on Interstate Cooperation (leadership panel chaired by the Senate President, used to absorb cannabis measures) are the decisive chokepoints (kslegislature SB 294; MPP).

Ballot initiatives

Kansas does not allow citizen-initiated statewide ballot measures. There is no statewide initiative or referendum process; the only routes to amend the constitution are a legislatively referred amendment (two-thirds vote of the legislature) or a constitutional convention. Kansas is among the 24 states without statewide initiative and referendum (Ballotpedia, laws governing ballot measures; State Court Report). As a result, there are no pending 2026 citizen cannabis, psychedelic, or drug-policy ballot measures; reform must pass the legislature. Some home-rule cities allow local initiative or referendum on ordinances, but this cannot reach state drug law (Ballotpedia, local ballot measures).

Equity and expungement

There is no cannabis social-equity licensing regime because there is no legal cannabis market. The 2026 medical bill HB 2678 reportedly included excise-tax revenue directed to child care, economic development, mental health, low-cost housing, and property tax relief, and contemplated expungement of certain cannabis offenses, but it did not advance (The Cannabis Business Advisors). General expungement in Kansas is petition-based (not automatic), with multi-year waiting periods and exclusions for serious violent offenses, so people with cannabis convictions can seek relief but must initiate and fund the petition themselves (Collateral Consequences Resource Center). Those excluded: anyone awaiting a future automatic mechanism (none exists) and anyone with ineligible offenses.

Market and barriers

There is no legal cannabis market, so there are no cannabis tax rates, license fees, capital or residency requirements, license caps, or licensee counts to report. The relevant numbers are prohibition penalties: first-offense possession can carry up to 6 months in jail and up to a 1,000 dollar fine (Kansas State Cannabis).

Hemp: producers license through the USDA federal program as of January 1, 2025 (no separate state producer fee schedule remains at the Kansas Department of Agriculture for production licensing) (Kansas Department of Agriculture). Specific current hemp fees are unconfirmed.

Enclosure read

Who is fenced out: Kansas patients (no medical access), adult consumers, small farmers and would-be cannabis entrepreneurs (no market to enter), and harm-reduction service providers (no syringe programs). The hemp sector, the one open lane, faces a double squeeze: a strict total-THC reading at the state level and the federal closure landing November 12, 2026, which would push most intoxicating hemp products out of legality.

Who is consolidating: In the absence of any state cannabis market, the beneficiaries of the status quo are out-of-state markets that capture Kansas demand (notably Missouri and Colorado dispensaries) and a single pharmaceutical actor, Compass Pathways, positioned to gain an exclusive, FDA-tied psilocybin pathway via HB 2218 while general psychedelic access stays criminalized. Political power is concentrated in one chokepoint: Senate leadership, which has repeatedly killed reform without floor votes.

Justification for score of 5/5 (corrected July 18, 2026; an earlier version of this brief scored Kansas 4): Kansas is fully fenced. It is one of the few states with neither adult-use nor functional medical cannabis, has no citizen ballot route to go around the legislature, has a veto-proof supermajority and a single leader explicitly committed to blocking reform, bans syringe services, and is about to see its one open lane (intoxicating hemp) federally curtailed. Under the July 2026 re-score, a state with no legal market scores as fully enclosed. The real harm-reduction wins (fentanyl test strips legal since 2023, statewide naloxone, the 2026 naloxone-expiration extension), the pharmaceutical psilocybin pathway, and the reform bills filed annually are all recorded above, but none of them opens the plant commons this score measures. The trajectory points the same direction as the score as the federal hemp deadline approaches.

What to watch next

  • November 12, 2026: federal hemp definition change and intoxicating-hemp ban take effect; watch how Kansas enforces against delta-8/THCA products after that date (Herb).
  • July 1, 2026: HB 2250 naloxone expiration extension reported effective (DCCCA).
  • August 4, 2026: gubernatorial primary; a post-Kelly governor could shift the executive posture on cannabis and harm reduction (KCUR).
  • January 2027: the next regular legislative session convenes (the 2026 session adjourned April 10, 2026). Bills not carried over must be refiled; federal Schedule III rescheduling of cannabis could add momentum to a 2027 medical push (MPP).
  • Watch whether Senate leadership control changes after the 2026 elections, since the chief reform chokepoint is the Senate President's chair.

Regulators

  • Hemp: U.S. Department of Agriculture administers hemp producer licensing in Kansas as of January 1, 2025; the Kansas Department of Agriculture historically handled industrial hemp and retains an industrial hemp program role (Kansas Department of Agriculture). Hemp processing oversight was moved to the Kansas State Fire Marshal (Cannabis Business Times). The Kansas Bureau of Investigation conducts criminal history checks for hemp license applicants.
  • Cannabis: No cannabis regulatory agency exists because there is no legal cannabis program. Enforcement runs through ordinary criminal law (local law enforcement, county/district attorneys, and the KBI).
  • Harm reduction: Kansas Department of Health and Environment and contracted providers such as DCCCA administer naloxone and overdose-prevention programs (DCCCA).
  • Controlled substances scheduling (relevant to the psilocybin carve-out) sits under the state controlled substances act, administered through the Board of Pharmacy and law enforcement; specifics for HB 2218 implementation are unconfirmed.

Federal exposure (2026)

Kansas is a near-prohibition state, so most federal cannabis levers that matter elsewhere pass over it without effect. The federal action still reshapes the one open lane (hemp) and the harm-reduction edges.

Rescheduling and 280E: The DOJ/DEA order signed April 22, 2026 and effective April 28, 2026 (91 FR 22714) moved only FDA-approved cannabis drugs and state-licensed medical cannabis to Schedule III, ending the 280E tax penalty for that medical category alone; recreational cannabis stays Schedule I, and the broader DEA hearing that opened June 29, 2026 may slip to 2027 ([DEA/DOJ rescheduling, federal context 2026, unconfirmed citation]). For Kansas this relief is moot. There is no adult-use market and no functional medical program, so there are no state-licensed cannabis businesses to benefit from the end of 280E. Schedule III does not legalize cannabis, does not authorize interstate commerce, and does not cover state businesses, so it changes nothing on the ground in Kansas. At most, the federal reclassification gives reform advocates a rhetorical talking point for a future 2027 medical push; it confers no operating relief today.

Hemp and the November 12, 2026 cliff: This is the federal lever with real bite in Kansas. The FY2026 agriculture appropriations rider (Sec. 781, sponsor reported as Rep. Andy Harris R-MD, unconfirmed) narrows the federal hemp definition to a total-THC standard of roughly 0.4 mg THC per container, recriminalizing an estimated 90 to 95 percent of intoxicating hemp products effective November 12, 2026; the H.R. 7010 delay was not enacted and the 2026 Farm Bill (H.R. 7567, unconfirmed) keeps the ban (Herb; Legislative Analysis and Public Policy Association fact sheet). Because Kansas already reads its 0.3 percent ceiling as total THC and restricts many inhalable formats, the federal change tightens an already constrained lane rather than reversing a permissive one. The practical result: the delta-8 and THCA products that survive in Kansas today on the federal hemp footing lose that footing on November 12, 2026, and the state's strict total-THC posture leaves little room to preserve them. The exact post-deadline enforcement interaction is unconfirmed, but the direction is one-way toward closure.

Banking: Not applicable. SAFER Banking stalled in Congress, but even passage would be irrelevant to Kansas because there is no legal cannabis market and therefore no cannabis businesses needing depository access. The banking question only becomes live for Kansas if the state ever stands up a regulated program.

Psychedelics: The April 18, 2026 executive order, Accelerating Medical Treatments for Serious Mental Illness [https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/] plus FDA priority vouchers fast-track FDA review of psilocybin, MDMA, and ibogaine, but all three remain Schedule I and none is approved yet ([federal context 2026, unconfirmed citation]). This federal route maps directly onto the only live Kansas thread: the HB 2218 carve-out that would exempt an FDA-approved psilocybin drug (Compass Pathways COMP360) from the state controlled substances act (Kansas Reflector). The federal pathway is the gating event; if and when FDA approves a psilocybin drug, the Kansas carve-out activates a single pharmaceutical channel. General access stays criminalized at both levels. The federal lever here favors the FDA-pill incumbent, not broad therapeutic access.

Harm reduction: Kansas allows naloxone (statewide distribution, plus the reported HB 2250 expiration extension) and fentanyl test strips (legal since 2023), but bans syringe service programs (DCCCA; KCUR). The SAMHSA guidance of April 24, 2026 bars federal funds for fentanyl test strips, clean syringes, and sterile water, while naloxone remains federally supported ([federal context 2026, unconfirmed citation]). For Kansas this means the federally supported tool (naloxone) aligns with state policy, but the state's legal test-strip program loses a federal funding channel and now leans on state and private money such as the DCCCA distribution network. Syringe services, already illegal in Kansas, get no federal help either way, so the SAMHSA rule simply confirms the existing wall. On fentanyl supply, the HALT Fentanyl Act (July 17, 2025) permanently placed fentanyl-related substances in Schedule I, reinforcing the criminal-enforcement posture that already dominates Kansas drug policy.

Patient access and rights

This section covers what Kansas law does and does not protect for a medical cannabis patient: use inside a hospital, and the broader rights that follow a patient into work, housing, parenting, an organ transplant list, and school. It is information, not legal advice, and it reflects the law as of July 2026. Each point links to the primary statute.

Kansas has no comprehensive medical cannabis program. It offers only a narrow legal shield: under Claire and Lola's Law, codified at Kansas Statutes Section 21-5706, a person may raise an affirmative defense for possessing a low-THC CBD preparation. That is a defense in court, not a program, and it grants none of the protections a medical program provides.

Hospital access (Ryan's Law): Kansas has no hospital-access law. No statute requires a hospital or similar facility to let a patient use medical cannabis on site, so the decision is left to each facility's own policy. Seven states have now enacted a Ryan's Law protection (California in 2021, and Colorado, Delaware, Louisiana, Oregon, Virginia, and Washington in 2026), with Pennsylvania's bill pending; Kansas is not among them.

Broader protections: here the absence is the finding. A review of Kansas law found no statutory protection for a medical cannabis patient in any of the areas other states cover: not employment, not housing, not a custody or visitation dispute, not placement on an organ transplant list, and not school enrollment, and there is no general medical-care protection. In these situations the patient has no enforceable shield; the protection does not exist in state law today.

Out-of-state patients: Kansas has no program and does not recognize other states' medical cannabis cards.

The federal picture: the April 2026 federal move of state-licensed medical cannabis to Schedule III did not change any of this. Schedule III does not make dispensary cannabis a lawful prescription medicine, and it creates no hospital-use right and no employment, housing, custody, transplant, or school protection; only state law can create those, and Kansas has not.

Kansas Medical Cannabis Act bills were introduced in 2025 and 2026 but died in committee.

Sources: Kansas's Claire and Lola's Law, Kansas Statutes Section 21-5706.

Related reading from Drug Policy Watch: the Federal Drug Policy Brief, the Schedule III rescheduling explainer, and the 50-State Matrix.

Analysis: the enclosure read in depth

Who is fenced out in Kansas, and by what: The fencing here is unusually total because three barriers stack on top of one another. First, a single legislative gatekeeper: Senate President Ty Masterson chairs the leadership-controlled Committee on Interstate Cooperation and has rerouted a House-passed medical cannabis bill into it, and has said marijuana will not be decriminalized while he holds power (MPP). Second, a veto-proof Republican supermajority (Senate roughly 31-9, House roughly 88-37) that can override the Democratic governor, so even a sympathetic executive cannot force reform (KSNT). Third, no citizen ballot initiative: Kansas is among the states with no statewide initiative or referendum, so advocates cannot route around the legislature the way Missouri voters did (Ballotpedia; State Court Report). The people fenced out are Kansas patients (no medical access), adult consumers, small farmers and would-be cannabis entrepreneurs (no market to enter), people who inject drugs (no legal syringe services), and the hemp retailers and small processors who occupy the one open lane.

State-plus-federal interaction: The defining feature of Kansas is that the federal and state vectors point the same direction, toward enclosure, with almost no counter-pressure. Where a permissive state can use the April 2026 Schedule III move or banking reform to expand a market, Kansas has no market for those levers to touch, so federal liberalization is inert here. Meanwhile the federal levers that do reach Kansas are restrictive: the November 12, 2026 hemp recriminalization closes the only open lane, the SAMHSA funding rule defunds the state's legal test-strip program, and HALT Fentanyl hardens the enforcement default. The one federal pathway that could open something, FDA psilocybin approval, channels narrowly to a single pharmaceutical actor via HB 2218 rather than to broad access. Net effect: federal action subtracts from the Kansas commons and adds nothing to it.

Absence of commons counter-moves: In more open states, enclosure is at least contested by social-equity licensing, home-grow rights, expungement automation, syringe programs, or ballot initiatives. Kansas has essentially none of these counter-moves. There is no social-equity regime (no market), no home grow (no legal cannabis), no automatic expungement (relief is petition-based and self-funded), no syringe services, and no ballot route. The closest thing to a commons gain is harm reduction (naloxone and test strips), but even that is now partly defunded federally and does not extend to syringe access. There is no organized state-level effort to preserve intoxicating hemp ahead of the federal cliff comparable to the litigation or delay pushes seen elsewhere; SB 292 would have regulated rather than protected the category and did not pass. The commons is shrinking and largely undefended.

What to watch: (1) the November 12, 2026 hemp cliff and how aggressively Kansas enforces against delta-8/THCA afterward; (2) the August 4, 2026 gubernatorial primary and whether a post-Kelly executive shifts posture, though the supermajority limits how much that matters; (3) whether Senate leadership control changes after the 2026 elections, since the Senate President's chair is the single chokepoint; (4) FDA action on psilocybin, which would activate the HB 2218 pharmaceutical channel; (5) the January 2027 session, where federal Schedule III could be cited in a renewed medical push.

Justification for the enclosure score of 5/5 (corrected July 18, 2026; an earlier version of this brief scored Kansas 4): the enclosure is deep and structurally locked. Kansas is one of the few states with neither adult-use nor functional medical cannabis, has no citizen ballot route around the legislature, has a veto-proof supermajority plus a named leader committed to blocking reform, bans syringe services, and is about to lose its one open lane (intoxicating hemp) to a federal recriminalization that its own strict total-THC reading reinforces. The federal 2026 picture worsens the position: liberalizing levers (Schedule III, banking) are inert in a state with no market, while restrictive levers (hemp cliff, SAMHSA defunding, HALT Fentanyl) all bite. The earlier 4 rested on the genuine harm-reduction wins (legal fentanyl test strips, statewide naloxone, the reported HB 2250 expiration extension), the FDA-tied psilocybin pathway, and the reform bills still filed annually. The July 2026 re-score corrected that reading: those seams are real and stay recorded above, but they do not open the plant commons this score measures, and a state where the community has no legal market to enter is fully enclosed. The November 12, 2026 deadline only locks the gate it finds already shut.

Active legislation (2026)

The following are significant bills from the 2025-2026 biennium. None advanced before adjournment on April 10, 2026; bills not carried over are effectively dead for this biennium. This list is not exhaustive. For the long tail and live status, see LegiScan Kansas, the Kansas State Legislature site.

Beyond the live tracker

These measures are not in the live bill list below: some are not bills (executive orders, rules, referendums, or budgets), and some are proposals or prior-session measures the live tracker does not currently carry.

  • SB 292 Intoxicating hemp regulation (age-21 sales, labeling, potential potency caps) (Remained in committee; did not pass)
Bill Title/Topic Chamber Status Sponsor(s)
SB 294 Kansas Medical Cannabis Act (medical legalization) Senate Died in Senate Committee on Federal and State Affairs, April 10, 2026 Committee on Federal and State Affairs (introduction requested by Norine Spears on behalf of Kansas Cannabis Coalition Inc., Cannabis Justice Coalition, and Kansas Cannabis Chamber of Commerce) (kslegislature; BillTrack50)
HB 2678 Kansas Medical Cannabis Act (medical legalization) House Introduced Feb 4, 2026; moved to Committee on Interstate Cooperation Mar 16, 2026; no hearing; did not advance Democratic bill, reported ~28 sponsors; Rep. L. Ruiz among sponsors (full sponsor list unconfirmed) (LegiScan; FastDemocracy)
HB 2679 Adult Use Cannabis Regulation Act (adult-use legalization) House Introduced Feb 4, 2026; moved to Committee on Interstate Cooperation Mar 16, 2026; did not advance Democratic bill, ~19 sponsors; primary sponsor reported as Rep. Ford Carr (confirm via tracker) (LegiScan; kslegislature)
HB 2405 Adult Use Cannabis Regulation Act (adult-use legalization) House Introduced 2025; referred to House Committee on Federal and State Affairs Mar 10, 2025; dead Committee bill (specific named sponsor unconfirmed) (LegiScan; TrackBill)
SB 292 Intoxicating hemp regulation (age-21 sales, labeling, potential potency caps) Senate Remained in committee; did not pass Sponsor unconfirmed (Cannabis Regulations AI)
HB 2218 Carve-out exempting an FDA-approved psilocybin drug (Compass Pathways COMP360) from the controlled substances act House Requested by lobbyist on behalf of Compass Pathways; 2026 status unconfirmed Requested on behalf of Compass Pathways; legislative sponsor unconfirmed (Kansas Reflector)
HB 2250 Allows naloxone use up to 10 years past printed expiration House Reported effective July 1, 2026 Sponsor unconfirmed (bill number per DCCCA program page) (DCCCA)

A separate set of bills "to decriminalize marijuana" was introduced in February 2026 per local reporting; specific bill numbers and sponsors beyond those above are unconfirmed (KWCH, Feb 2026).

Support this work

This work is free and reader-funded. No paywalls, no ads. This brief is independent and fully sourced, and reader contributions are what keep the 50-state coverage current and answerable to readers, not advertisers or owners.

If it helped you, please chip in $5 to keep it going. Recurring support helps most; about $25 funds a full refresh of a state brief like this one.

Contribute $5 on Ko-fi Become a member

← Back to all 50 states and federal briefs

A planning snapshot for 2026, not legal advice. Policy moves quickly; confirm any single detail against the cited sources before acting on it. Sponsor names are given where confirmable and marked unconfirmed otherwise.

About the author. Jessica Mantonya is the founder of Drug Policy Watch and Hold in Common. She also advises operators, advocates, and funders on regulatory strategy and anti-enclosure positioning. Work with her →

Sources